Acalabrutinib maleate is an oral medication used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [1]. It is a Bruton's tyrosine kinase (BTK) inhibitor [1].
What is Acalabrutinib Maleate Used For?
Acalabrutinib maleate is prescribed for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2]. It is also indicated for adults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2].
How Does Acalabrutinib Maleate Work?
As a BTK inhibitor, acalabrutinib maleate works by blocking the action of a protein called Bruton's tyrosine kinase [1]. This protein is important for the growth and survival of certain white blood cells, including cancerous B cells [1]. By inhibiting BTK, acalabrutinib maleate helps to reduce the number of these abnormal cells [1].
When Can I Expect Generic Acalabrutinib Maleate?
The patent expiry for acalabrutinib maleate is a key factor in the availability of generic versions. According to DrugPatentWatch.com, the patent landscape for acalabrutinib is complex, with multiple patents covering different aspects of the drug [3]. Specific patent expiration dates can vary, and legal challenges can impact the timeline for generic entry [3].
What Are the Potential Side Effects of Acalabrutinib Maleate?
Common side effects associated with acalabrutinib maleate can include decreased platelet count, low red blood cell count, and low neutrophil count [2]. Patients may also experience diarrhea, fatigue, muscle pain, bruising, and headache [2]. More serious side effects can occur, such as bleeding, infections, heart rhythm problems, and secondary cancers [2]. It is important for patients to discuss any concerns about side effects with their healthcare provider [2].
How Does Acalabrutinib Compare to Other BTK Inhibitors?
Acalabrutinib is a second-generation BTK inhibitor, designed to offer improved selectivity compared to first-generation drugs like ibrutinib [4]. This improved selectivity aims to reduce off-target effects, potentially leading to a better safety profile [4]. Other BTK inhibitors in use include zanubrutinib and tirabrutinib [4]. The choice of BTK inhibitor often depends on the specific type of lymphoma, patient characteristics, and physician preference [4].
What Are the Clinical Trial Results for Acalabrutinib Maleate?
Clinical trials have demonstrated the efficacy of acalabrutinib maleate in treating MCL and CLL/SLL. In studies for MCL, acalabrutinib showed significant improvement in progression-free survival compared to standard therapies [5]. For CLL/SLL, acalabrutinib has been shown to be effective in achieving high response rates and prolonged progression-free survival [5].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.nhs.uk/medicines/acalabrutinib/
3. https://www.drugpatentwatch.com/drug/acalabrutinib
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348523/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa2114065